BPIQ Blog

First published 3/6/23 - currently in progress Summary: ESPR CLEAR outcomes data from NEXLETOL trial reported over the weekend at ACC.23...

Last week was a green week for XBI (biotech ETF), which finished the week up +2.3%, see the biggest news from last week, including a full...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: Several recent oncology investor conferences are still available to the public, including all company webcasts These conferences...

First posted 3/10/2023; last updated 5/1/2023 Summary: Many exciting rare diseases catalysts are coming throughout the year See the table...

Last week was a tough week for biotech, XBI (biotech ETF) saw a 6% pullback, see the biggest news from last week, including a full table...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Summary: Reata Pharmaceuticals has a PDUFA data for Omaveloxolone for FA 2/28/23. The previous PDUFA date was extended 3 months after...

Summary: The upcoming readout from ETNB includes Phase 2b data from the pegozafermin trial in NASH. This is a Suspected Mover for Q1...

Last updated 4/11/23 Summary: Many exciting blood cancer & disease catalysts are coming throughout the year See the table below for some...